Abstract
OBJECTIVES To evaluate the latest evidence concerning the efficacy of conbercept on vitrectomy for proliferative diabetic retinopathy (PDR) and its efficacy compared to control and other antivascular endothelial growth factor. METHODS We performed a systematic literature search on topics that assess the role of conbercept in patients undergoing vitrectomy for PDR from inception to November 2019, using PubMed, EuropePMC, Cochrane Central Database, ProQuest, ScienceDirect, and Clinicaltrials.gov. Two researchers independently searched literature, extracted data, and evaluated the risk of bias. RevMan 5.3 and StataMP 16 software were used to perform data analysis. RESULTS There were 699 cases (eyes) from eight studies. Baseline best-corrected visual acuity (BCVA) was better in the control group compared to conbercept group (mean difference [MD] = 0.13, I2 = 0%). A greater BCVA improvement was observed in the conbercept group after 1-month (MD = -0.27, I2 = 1%), 3-month (MD = -0.28, I2 = 0%), and 6-month (MD = -0.20, I2 = 78%) follow-up. The need for endodiathermy (odds ratio [OR] = 0.20, I2 = 0%) and silicone oil tamponade use (OR = 0.59, I2 = 72%) and intraoperative bleeding (OR = 0.11, I2 = 33%) was lower in conbercept group. Postoperative early (OR = 0.22, I2 = 0%) and late (OR = 0.47, I2 = 0%) vitreous hemorrhage was lower in conbercept group. There was no significant difference in BCVA improvement and intraoperative outcome between conbercept and ranibizumab. CONCLUSIONS Intravitreal conbercept was associated with a more significant BCVA improvement, better intraoperative outcome, and less postoperative vitreous hemorrhage compared to no conbercept.
